Clozapine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Clozapine

Clozapine (sold as Clozaril®, Leponex®, Fazaclo®) was the first of the atypical antipsychotics to be developed. It was approved by the United States FDA in 1989 and is the only FDA-approved medication indicated for treatment-resistant schizophrenia and for reducing the risk of suicidal behaviour in patients with schizophrenia. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

History and main uses

Clozapine was developed by Sandoz in 1961, and introduced in Europe ten years later. In 1975, after reports of agranulocytosis leading to death in some clozapine-treated patients, Clozapine was voluntarily withdrawn by the manufacturer. Clozapine fell out of favor for more than a decade. However, when studies demonstrated that clozapine was more effective against treatment-resistant schizophrenia than other antipsychotics, the FDA and health authorities in most other countries approved its use only for treatment-resistant schizophrenia, and required regular haematological monitoring to detect granulocytopenia, before agranulocytosis develops. In December of 2002, Clozapine was also approved for reducing the risk of suicide in schizophrenic or schizoaffective patients judged to be at chronic risk for suicidal behavior.

Commonly approved indications

  • Treatment-resistant schizophrenia, if the required hematologic monitoring is adhered to
  • Reducing the risk of suicide in schizophrenic or schizoaffective patients judged to belong to a high risk group with chronic risk for suicidal behavior. Clozapine was shown to prolong the time to suicidal attempt significantly greater than Olanzapine (Zyprexa®).

Clozapine works equally well against positive (e.g. delusions, hallucinations) and negative (e.g. emotional and social withdrawal) symptoms of schizophrenia. It has no dyscognitive effect often seen with other psychoactive drugs and is even able to increase the capabilities of the patient to react to this environment and thereby fosters social rehabilitation.

Off-label and investigational drug use

  • Treatment of psychosis in L-Dopa treated patients (25 to 50 mg at bedtime is often sufficient); this indication is currently approved in Switzerland
  • Treatment of otherwise resistant acute episodes of mania
  • Treatment of psychotic symptoms occurring in patients with dementia of the Levy-body-type
  • Treatment of severe cases of obsessive compulsive disorder
  • Treatment of intractable chronic insomnia, if all other measurements have failed

Though much research has been done evaluating the benefit of clozapine in treating the aforementioned conditions, it is too early to come to a conclusive result. If you contemplate clozapine as drug for these conditions, weigh carefully benefits and risks and inform the patients fully, if possible, about the advantages and risks of clozapine treatment, before a joint decision is made. If the patient is not able to make own decisions, parents or guardians or the competent court must give their consent.

Chemistry

Clozapine is yellow crystalline solid with melting point 183-184 °C. It is insoluble in water, soluble in acetone, very well soluble in chloroform. Chemical name is <8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzodiazepine>.

Read more at Wikipedia.org


[List your site here Free!]


Differential Effects of Haloperidol and Clozapine on Motor Recovery after Sensorimotor Cortex Injury in Rats
From Journal of Neurologic Physical Therapy, 12/1/03 by Rizzolo, Jaime

Abstracts

Differential Effects of Haloperidol and Clozapine on Motor Recovery after Sensorimotor Cortex Injury in Rats. Goldstein LB, Bullman S. Neurorebabil Neural Repair. 2002; 16:321-325.

Several previous studies in the literature examine the effects of haloperidol on post brain injury recovery. The specific purpose of this study was to compare the relative effects of haloperidol and clozapine on motor recovery after unilateral sensorimotor cortex injury in rats. The authors hypothesized that haloperidol's antagonistic effects at the noradrenergic receptors would result in a relatively negative effect on motor recovery when compared to clozapine.

One hundred forty two Male Sprague-Dawley rats were obtained from Charles River Breeding Laboratories, Inc. in Raleigh, NC and housed in a controlled environment. Each rat was expected to negotiate a 2.5cm x 122cm elevated wooden beam surrounded by associated bright lights and white noise which served as avoidance and activating stimuli. Training on the behavioral testing apparatus was performed with each rat until it consistently traversed the beam without difficulty.

Following training, groups of 16 rats underwent right sided craniotomies. Surgical control rats also underwent the identical surgical procedure, but craniotomies were not performed. The day after surgery, rats (n= 3-4 per group) were given either a single dose of saline vehicle or a single dose of haloperidol (either 0.1, 1.0, or 10.0mg/kg;intraperitoneal). In separate experiments, another group of 16 rats (n= 3-4 per group) that underwent cortex surgery received either a single dose of saline vehicle or a single dose of clozapine (0.1, 0.5, or 1.0mg/kg; intraperitoneal). The effects of these drugs on beam-walking performance in sham cortex-lesioned rats were tested in separate experiments.

Behavioral testing was performed at 1 hour intervals for 6 hours following drug administration and then daily over the subsequent 12 days by an observer blind to the study hypothesis. Motor performance was rated on an ordinal 7 point scale.

Statistical analysis of data collected was performed using repeated-measures analysis of variance (ANOVAs), post-hoc Fisher least significant difference (LSD), Kruskalis-Wallis test, and the post-hoc Dunn procedure. The final results indicated that haloperidol impaired overall motor recovery (ANOVA F[3, 42], P=0.0()2) at each tested dose (Fisher LSD P > 0.01, respectively) with no significant differences between the doses (Fisher LSD P

Based on these findings, the authors conclude that a single dose of haloperidol given the day after sensorimotor cortex injury has a long-lasting, detrimental effect of subsequent functional locomotor recovery. The effect was present even at the lowest dose tested (0.1mg/kg) and was still evident 2 weeks later. In contrast to the effects of haloperidol, there was no detrimental effect of clozapine when given at low dose (0.1mg or 0.5mg/kg), with only the highest dose group differing from controls. Although the authors acknowledge the limitations of applying the conclusions of animal studies to clinical practice, they suggest that based on the results of this study and several prior studies, the use of low doses of clozapine may provide a safer alternative to haloperidol in the treatment of agitated patients recovering from strokes.

Jaime Rizzolo, Student UMDNJ

Morriston Memorial Hospital

Copyright Neurology Report Dec 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Clozapine
Home Contact Resources Exchange Links ebay